세계의 COVID-19 임상시험 시장 : 제품, 단계별 예측(2025-2030년)

The COVID-19 Clinical Trials Market was valued at USD 5.95 billion in 2023, expected to reach USD 6.79 billion in 2024, and is projected to grow at a CAGR of 13.93%, to USD 14.84 billion by 2030.

The scope of COVID-19 clinical trials encompasses a broad range of investigational studies aimed at evaluating potential therapeutics and vaccines to combat the coronavirus. These trials are necessary due to the urgent need for effective treatments and preventive measures to control and mitigate the impact of the pandemic. The application extends across various disciplines, including virology, immunology, pharmacology, and epidemiology, while the end-use scope includes clinical settings, pharmaceutical companies, research institutions, and regulatory bodies. Market insights reveal that factors such as increased government funding, unprecedented collaboration between public and private sectors, and accelerated regulatory approvals are key drivers of growth. The growing prevalence of COVID-19 variants and the subsequent need for booster vaccines present significant opportunities for continued research and development. Innovations in drug delivery systems and the use of AI in trial designs can significantly enhance the effectiveness and efficiency of trials. However, limitations and challenges such as the rapid mutation of the virus, recruitment hurdles, ethical concerns, and logistical complexities can impede progress. Furthermore, vaccine hesitancy and inequitable distribution pose considerable challenges in achieving widespread immunity. The best areas for innovation include mRNA technology advancements, the development of broad-spectrum antivirals, and personalized medicine approaches tailored to demographic variances in response to treatment. To capitalize on market opportunities, stakeholders should focus on patient-centric trial designs, leveraging digital platforms for data collection, and fostering diversified global partnerships. Adopting a responsive and adaptive trial methodology will also address dynamic regulatory changes and facilitate prompt market entry. Overall, the nature of the COVID-19 clinical trials market is highly dynamic, characterized by rapid scientific advancements and an urgent demand for solutions. Continuous monitoring of emerging trends and proactive engagement with key stakeholders will be essential in navigating its complexities and maximizing growth potential.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving COVID-19 Clinical Trials Market

The COVID-19 Clinical Trials Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rapid Spread of Coronavirus Resulting in a Large Number of Deaths
  • Government Support and Grants for COVID-19 Clinical Trials
  • Increasing Research and Development (R&D) Initiatives for Effective Therapeutics
• Market Restraints
  • Complexities in Clinical Trial Management and Risk of Side Effects During Trials
• Market Opportunities
  • Collaborative Efforts of Pharma and Technology Firms
  • Rising Investment from Importing Countries
• Market Challenges
  • Limited Supportive Infrastructure, Skills, and Technology in Developing Areas Around the World

Porter's Five Forces: A Strategic Tool for Navigating the COVID-19 Clinical Trials Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the COVID-19 Clinical Trials Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the COVID-19 Clinical Trials Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the COVID-19 Clinical Trials Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the COVID-19 Clinical Trials Market

A detailed market share analysis in the COVID-19 Clinical Trials Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the COVID-19 Clinical Trials Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the COVID-19 Clinical Trials Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the COVID-19 Clinical Trials Market, highlighting leading vendors and their innovative profiles. These include GlaxoSmithKline PLC, Novavax, Inc., Moderna, Inc., IQVIA Inc., PPD, Inc. by Thermo Fisher Scientific, Inc., Sanofi SE, PAREXEL International Corporation, Laboratory Corporation of America Holdings, Inovio Pharmaceuticals, Inc., Novartis AG, Medidata Solutions, Quanticate, Johnson & Johnson Services, Inc., ICON PLC, Takeda Pharmaceutical Company Limited, Merck & Co., Inc., Novotech, Pfizer Inc., GeoVax, Valneva SE, Bharat Biotech Ltd., AbbVie Inc., Regeneron Pharmaceuticals, Inc., Clario, Gilead Sciences, Inc., and BioNTech SE.

Market Segmentation & Coverage

This research report categorizes the COVID-19 Clinical Trials Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Therapeutics and Vaccines.
• Based on Phase, market is studied across Phase I, Phase II, Phase III, and Phase IV.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rapid Spread of Coronavirus Resulting in a Large Number of Deaths
    • 5.1.1.2. Government Support and Grants for COVID-19 Clinical Trials
    • 5.1.1.3. Increasing Research and Development (R&D) Initiatives for Effective Therapeutics
  • 5.1.2. Restraints
    • 5.1.2.1. Complexities in Clinical Trial Management and Risk of Side Effects During Trials
  • 5.1.3. Opportunities
    • 5.1.3.1. Collaborative Efforts of Pharma and Technology Firms
    • 5.1.3.2. Rising Investment from Importing Countries
  • 5.1.4. Challenges
    • 5.1.4.1. Limited Supportive Infrastructure, Skills, and Technology in Developing Areas Around the World
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product: Increased adoption of antiviral medications to control COVID-19 virus replication
  • 5.2.2. Phase: Significance of Phase IV clinical trials for post-marketing surveillance of approved drugs
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. COVID-19 Clinical Trials Market, by Product

• 6.1. Introduction
• 6.2. Therapeutics
• 6.3. Vaccines

7. COVID-19 Clinical Trials Market, by Phase

• 7.1. Introduction
• 7.2. Phase I
• 7.3. Phase II
• 7.4. Phase III
• 7.5. Phase IV

8. Americas COVID-19 Clinical Trials Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific COVID-19 Clinical Trials Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa COVID-19 Clinical Trials Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
  • 11.3.1. ICON Partners with US Government for Clinical Trials of Covid-19 Vaccines
  • 11.3.2. NIH Launches Clinical Trials for Long COVID Treatments
  • 11.3.3. Moderna Clinical Trial Data Confirm Its Updated COVID-19 Vaccine Generates Robust Immune Response in Humans Against Widely Circulating Variants

Companies Mentioned

• 1. GlaxoSmithKline PLC
• 2. Novavax, Inc.
• 3. Moderna, Inc.
• 4. IQVIA Inc.
• 5. PPD, Inc. by Thermo Fisher Scientific, Inc.
• 6. Sanofi SE
• 7. PAREXEL International Corporation
• 8. Laboratory Corporation of America Holdings
• 9. Inovio Pharmaceuticals, Inc.
• 10. Novartis AG
• 11. Medidata Solutions
• 12. Quanticate
• 13. Johnson & Johnson Services, Inc.
• 14. ICON PLC
• 15. Takeda Pharmaceutical Company Limited
• 16. Merck & Co., Inc.
• 17. Novotech
• 18. Pfizer Inc.
• 19. GeoVax
• 20. Valneva SE
• 21. Bharat Biotech Ltd.
• 22. AbbVie Inc.
• 23. Regeneron Pharmaceuticals, Inc.
• 24. Clario
• 25. Gilead Sciences, Inc.
• 26. BioNTech SE